Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Makiya

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptorZhaochun Chen, Elizabeth R Fischer, Diana Kouiavskaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2020
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa InfectionFanny Legrand, Jesica Herrick, Michelle Makiya, et al.
Journal of Neuroinflammation|September 27, 2025
Eosinophil recruitment and activation in the central nervous system of patients with subarachnoid neurocysticercosisEmily Miltenberger, Janitzio Guzmán, Rodaba Rahim, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 14, 2022
Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal DiseaseFei Li Kuang, Michelly Sampaio De Melo, Michelle Makiya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2017
Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa InfectionJesica A Herrick, Fanny Legrand, Raceline Gounoue, et al.
Blood|July 14, 2020
Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migrationSo Gun Hong, Noriko Sato, Fanny Legrand, et al.
Blood|May 10, 2018
Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromesSandhya R Panch, Michael E Bozik, Thomas Brown, et al.
Blood|December 14, 2016
Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrheaChi A Ma, Liqiang Xi, Brian Cauff, et al.
International Journal of Molecular Sciences|June 27, 2024
Immune Response Dynamics and Biomarkers in COVID-19 PatientsMaral Ranjbar, Ruth P Cusack, Christiane E Whetstone, et al.
The New England Journal of Medicine|April 4, 2019
Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic SyndromeFei Li Kuang, Fanny Legrand, Michelle Makiya, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptorZhaochun Chen, Elizabeth R Fischer, Diana Kouiavskaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2020
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa InfectionFanny Legrand, Jesica Herrick, Michelle Makiya, et al.
Journal of Neuroinflammation|September 27, 2025
Eosinophil recruitment and activation in the central nervous system of patients with subarachnoid neurocysticercosisEmily Miltenberger, Janitzio Guzmán, Rodaba Rahim, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 14, 2022
Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal DiseaseFei Li Kuang, Michelly Sampaio De Melo, Michelle Makiya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2017
Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa InfectionJesica A Herrick, Fanny Legrand, Raceline Gounoue, et al.
Blood|July 14, 2020
Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migrationSo Gun Hong, Noriko Sato, Fanny Legrand, et al.
Blood|May 10, 2018
Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromesSandhya R Panch, Michael E Bozik, Thomas Brown, et al.
Blood|December 14, 2016
Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrheaChi A Ma, Liqiang Xi, Brian Cauff, et al.
International Journal of Molecular Sciences|June 27, 2024
Immune Response Dynamics and Biomarkers in COVID-19 PatientsMaral Ranjbar, Ruth P Cusack, Christiane E Whetstone, et al.
The New England Journal of Medicine|April 4, 2019
Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic SyndromeFei Li Kuang, Fanny Legrand, Michelle Makiya, et al.
Pageof 2